Jesse Shefferman Net Worth

The estimated Net Worth of Jesse Shefferman is at least $2.75 Million dollars as of 11 August 2022. Mr Shefferman owns over 9,065 units of Protara Therapeutics Inc stock worth over $1,495,050 and over the last 5 years he sold TARA stock worth over $0. In addition, he makes $1,255,836 as Co-Founder, CEO, and Pres & Director at Protara Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Shefferman TARA stock SEC Form 4 insiders trading

Mr has made over 1 trades of the Protara Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 9,065 units of TARA stock worth $34,810 on 11 August 2022.

The largest trade he's ever made was buying 9,065 units of Protara Therapeutics Inc stock on 11 August 2022 worth over $34,810. On average, Mr trades about 604 units every 0 days since 2020. As of 11 August 2022 he still owns at least 879,441 units of Protara Therapeutics Inc stock.

You can see the complete history of Mr Shefferman stock trades at the bottom of the page.

Mr. Jesse Shefferman biography

Jesse Shefferman is the Co-Founder, CEO, Pres & Director at Protara Therapeutics Inc.

What is the salary of Mr Shefferman?

As the Co-Founder, CEO, and Pres & Director of Protara Therapeutics Inc, the total compensation of Mr Shefferman at Protara Therapeutics Inc is $1,255,836. There are no executives at Protara Therapeutics Inc getting paid more.

How old is Mr Shefferman?

Mr Shefferman is 49, he's been the Co-Founder, CEO, and Pres & Director of Protara Therapeutics Inc since . There are 6 older and 7 younger executives at Protara Therapeutics Inc. The oldest executive at Protara Therapeutics Inc is Roger Garceau, 66, who is the Independent Director.

What's Mr Shefferman's mailing address?

Jesse's mailing address filed with the SEC is C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK, NY, 10010.

Insiders trading at Protara Therapeutics Inc

Over the last 5 years, insiders at Protara Therapeutics Inc have traded over $3,287,540 worth of Protara Therapeutics Inc stock and bought 250,034 units worth $1,947,929 . The most active insiders traders include Management Inc. Opaleye, Richard S Levy, and Gregory Sargen. On average, Protara Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $34,731. The most recent stock trade was executed by Management Inc. Opaleye on 9 September 2024, trading 61,992 units of TARA stock currently worth $114,065.

What does Protara Therapeutics Inc do?

protara therapeutics, inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. the company's lead program is tara-002, an investigational cell therapy for the treatment of lymphatic malformations. it also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. the company was formerly known as artara therapeutics, inc. and changed its name to protara therapeutics, inc. in may 2020. protara therapeutics, inc. is based in new york, new york.

Complete history of Mr Shefferman stock trades at Protara Therapeutics Inc

Protara Therapeutics Inc executives and stock owners

Protara Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jesse Shefferman,
  Co-Founder, CEO, Pres & Director
• Blaine T. Davis,
  CFO, Principal Financial & Accounting Officer and Sec.
• Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D.,
  Chief Scientific Operations Officer
• Jesse Shefferman,
  President, Chief Executive Officer, Director
• Jacqueline Zummo,
  Senior Vice President - Research Operations
• Luke Beshar,
  Chairman of the Board
• Roger Garceau,
  Independent Director
• Michael Solomon,
  Independent Director
• Gregory Sargen,
  Independent Director
• Richard Levy,
  Independent Director
• Barry Flannelly,
  Director
• Blaine Davis,
  Chief Financial Officer
• Kristine Rosse,
  Sr. VP & Chief People Officer
• Justine O'Malley,
  Sr. VP of Investor Relations & Corp. Affairs
• Hannah Fry,
  Principal Accounting Officer & Controller
• Mary J. Grendell,
  Corp. Sec.
• Dr. Jathin Bandari M.D.,
  Interim Chief Medical Officer, VP & Head of Clinical Devel.
• Dr. Martin Sebastian Olivo M.D.,
  Chief Medical Officer
• Management Inc. Opaleye,
  10% owner
• Scott Braunstein,
  Director
• L.P. Opaleye,,
  10% owner
• Randall Marshall,
  
• Hannah Fry,
  VP, Controller
• Julio Casoy,
  Chief Medical Officer
• Martin Sebastian Olivo,
  Chief Medical Officer
• Jathin Bandari,
  Chief Medical Officer
• Patrick Fabbio,
  Chief Financial Officer
• Cynthia Smith,
  
• Jane Huang,